Liu Y. How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?. MS [Internet]. 2024 Dec. 31 [cited 2026 Nov. 4];2(6):2912. Available from: https://ms.deanfrancis.press/article/view/1005